BioCentury on BioBusiness,
Incoming Shire CEO outlines ophthalmics strategy after SARcode, Premacure deals
Shire sees opportunity
Monday, April 1, 2013
With two ophthalmics deals in as many weeks, Shire plc
has revealed the next specialty area in which it wants a foothold. The company
believes the small size of the ophthalmic practitioner population - about
42,000 in the U.S. - as well as the availability of novel targets, make it a
The first deal came on March 12
when Shire announced the acquisition of Premacure AB. The Swedish company's
Premiplex (formerly iPlex) is in Phase II testing to prevent retinopathy of
prematurity (ROP), a rare disease that primarily affects premature infants and
can lead to blindness. The protein replacement therapy includes a complex of
insulin-like growth factor-1 (IGF-1) and its principal binding protein,
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]